Complete remission of del(5q) myelodysplastic syndrome after 7 days of lenalidomide therapy gives an alert!

Case Reports in Oncology

Volumn 5, Issue 3, 2012, Pages 586-591

  Al Jafar, Hassan A ^a   Al Azmi, Salih ^a   Qassem, J A ^a   Hasan, Eman A ^a   Alduaij, Arwa ^a  

^a AL AMIRI HOSPITAL   (Kuwait)

Author keywords

5q del; Blood transfusion; Lenalidomide; Myelodysplastic syndrome; Remission

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; CYTOTOXIC AGENT; HEMOGLOBIN; LENALIDOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

5Q- SYNDROME; ADULT; ARTICLE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; CHEST INFECTION; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION 5; DRUG DOSE REDUCTION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; MACROCYTIC ANEMIA; MAINTENANCE CHEMOTHERAPY; MEAN CORPUSCULAR VOLUME; PALLOR; PANCYTOPENIA; PRIORITY JOURNAL; REMISSION; SCLERITIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; WEAKNESS;

EID: 84873208586     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000345098     Document Type: Article

References (10)

1. Cheson BD: The Myelodysplastic Syndromes. The Oncologist 1997;2:28-39.
2. Warlick ED, Smith BD: Myelodysplastic syndromes: Review of pathophysiology and current novel treatment approaches. Curr Cancer Drug Targets 2007;7:541-558.
3. Steensma DP, Tefferi A: The myelodysplastic syndrome(s): A perspective and review, highlighting current controversies Leuk Res 2003;27:95-120.
4. Koreth J, Antin JH: Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. Hematologica 2010;95:364-366.
5. Fehniger TA, Byrd JC: Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009;113:1002-1005.
6. Mufti GJ, Bennett JM, Goasguen J, et al: Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008;93:1712-1717.
7. List AF, Baker AF, Green S, Bellamy W: Lenalidomide: Targeted anemia therapy for myelodysplastic syndromes. Malignant Hematology Program, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
8. List AF, Baker AF, Green S, et al: Lenalidomide: Targeted anemia therapy for myelodysplastic syndromes. Cancer Control 2006;13(suppl):4-11.
9. Kiaei M, Petri S, Kipiani K, et al: Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26:2467-2473.
10. Komrokji RS, List AF: Role of lenalidomide in the treatment of myelodysplastic syndromes. Semin Oncol 2011;38:648-657.